Our retrospective study showed that InsulinAPP application with this use of human insulins is effective and safe in the management of patients with T2D on the hospitalist-managed ward, with more than 70% BG measurements within the therapeutic range and a low rate of hypoglycemia. This evidence concerns the gene INS and Hypoglycemia.